Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A recent report in Cancer again seems to suggest that men with prostate cancer treated by radical prostatectomy (RP) who have a long time to biochemical recurrence (BCR) or a long PSA doubling time after BCR may have no higher overall risk of death than men who have no BCR at all.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical recurrence, mortality, PSA doubling time, radical prostatectomy | 1 Comment »
The House Committee on Oversight and Government Reform (Chairman: Ed Towns, D, NY) is to hold a congressional hearing on “Prostate Cancer: New Questions About Screening and Treatment” on Thursday March 4. The hearing is open to the public.
Filed under: Living with Prostate Cancer | Tagged: Congressional hearing | Leave a Comment »
Myriad Genetics has announced the launch of a 46-gene prognostic test which is supposed to be able to determine the risk of prostate cancer recurrence in patients who have undergone a radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gene test, prognosis, PROLARIS, recurrence | 2 Comments »
The “New” Prostate Cancer InfoLink stated a while ago that the FDA would not convene a second advisory committee meeting to discuss the results of the IMPACT trial.
Filed under: Drugs in development, Management, Treatment | Tagged: Provenge, sipuleucel-T | Leave a Comment »
A new mini-review article in BJU International provides additional insights into the potential uses of the PCA3 test in clinical practice.
Filed under: Diagnosis, Management, Risk | Tagged: PCA3, prostate cancer gene 3, test | 3 Comments »
A new paper in the Proceedings of the National Academy of Science proposes the potential of a whole new class of agents in the treatment of prostate cancer.
Filed under: Drugs in development, Treatment | Tagged: ERβ agonist, estrogen receptor-β, Treatment | 2 Comments »
In the U.S. House of Representatives, Jim Marshall (GA) and Peter King (NY) are currently circulating a letter to colleagues asking for their support for increased funding for the Prostate Cancer Research Program (PCRP) — part of the Congressionally Directed Medical Research Program at the Department of Defense. This is the ONLY federally funded research [...]
Filed under: Uncategorized | Comments Off
Over the years there has been a lot of discussion, but few hard facts, about the impact of soy consumption on PSA levels in men with progressive prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, isoflavones, PSA, soy milk | 2 Comments »
According to a media release issued on February 19, Kinex Pharmaceuticals (a US-based biopharmaceutical company) has initiated a Phase II clinical trial to evaluate the safety and efficacy of KX2-391 in patients with castration-resistant prostate cancer (CRPC) that has metastasized to bone. Eligible patients can not have received prior chemotherapy.
Filed under: Drugs in development | Tagged: KX2-391 | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site